Literature DB >> 18197723

Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Benjamin C T Field1, Alison M Wren, Dunstan Cooke, Stephen R Bloom.   

Abstract

Food intake and bodyweight are tightly regulated by the brainstem, hypothalamus and reward circuits. These centres integrate diverse cognitive inputs with humoral and neuronal signals of nutritional status. Our knowledge of the role of gut hormones in this complex homeostatic system has expanded enormously in recent years. This review discusses both the role of gut hormones in appetite regulation, and the current state of development of gut hormone-based obesity therapies, with a particular focus on pancreatic polypeptide, peptide YY, amylin, glucagon-like peptide-1, oxyntomodulin, cholecystokinin and ghrelin. Several gut hormone-based treatments for obesity are under investigation in phase II and III clinical trials, and many more are in the pipeline.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18197723     DOI： 10.2165/00003495-200868020-00002

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  231 in total

1.  Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats.

Authors:  Prasanth K Chelikani; Alvin C Haver; Joseph R Reeve; David A Keire; Roger D Reidelberger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-10-06       Impact factor: 3.619

2.  Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis.

Authors:  F Malaisse-Lagae; J L Carpentier; Y C Patel; W J Malaisse; L Orci
Journal:  Experientia       Date:  1977-07-15

3.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.

Authors:  D E Cummings; J Q Purnell; R S Frayo; K Schmidova; B E Wisse; D S Weigle
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

4.  Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells.

Authors:  L I Larsson; F Sundler; R Håkanson
Journal:  Cell Tissue Res       Date:  1975       Impact factor: 5.249

5.  Amylin decreases meal size in rats.

Authors:  T A Lutz; N Geary; M M Szabady; E Del Prete; E Scharrer
Journal:  Physiol Behav       Date:  1995-12

6.  Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion.

Authors:  A S Rocca; P L Brubaker
Journal:  Endocrinology       Date:  1999-04       Impact factor: 4.736

7.  Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.

Authors:  R A Liddle; I D Goldfine; M S Rosen; R A Taplitz; J A Williams
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

8.  Satiety effects of cholecystokinin in humans.

Authors:  R J Lieverse; J B Jansen; A M Masclee; C B Lamers
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

9.  Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract.

Authors:  M A Ghatei; L O Uttenthal; N D Christofides; M G Bryant; S R Bloom
Journal:  J Clin Endocrinol Metab       Date:  1983-09       Impact factor: 5.958

10.  Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats.

Authors:  J T Clark; P S Kalra; W R Crowley; S P Kalra
Journal:  Endocrinology       Date:  1984-07       Impact factor: 4.736
View more
  8 in total

Review 1.  The gut sensor as regulator of body weight.

Authors:  Thomas Reinehr; Christian L Roth
Journal:  Endocrine       Date:  2014-12-30       Impact factor: 3.633

2.  Is there altered sensitivity to ghrelin-receptor ligands in leptin-deficient mice?: importance of satiety state and time of day.

Authors:  Beate C Finger; Harriët Schellekens; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2011-03-05       Impact factor: 4.530

3.  Gliptins: a new class of oral antidiabetic agents.

Authors:  K G Seshadri; M H B Kirubha
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

4.  Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.

Authors:  Min He; Haoran Su; Weiwei Gao; Stina M Johansson; Qing Liu; Xiaoyan Wu; Jiayu Liao; Andrew A Young; Tamas Bartfai; Ming-Wei Wang
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

5.  Pharmacological management of binge eating disorder: current and emerging treatment options.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Anne M O'Melia
Journal:  Ther Clin Risk Manag       Date:  2012-05-08       Impact factor: 2.423

6.  Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach.

Authors:  Theodoros Papathanasiou; Anders Strathe; Henrik Agersø; Trine Meldgaard Lund; Rune Viig Overgaard
Journal:  Diabetes Obes Metab       Date:  2020-02-19       Impact factor: 6.577

Review 7.  Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.

Authors:  Mª Luisa Isidro; Fernando Cordido
Journal:  Pharmaceuticals (Basel)       Date:  2010-01-12

8.  Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.

Authors:  M E J Lean; R Carraro; N Finer; H Hartvig; M L Lindegaard; S Rössner; L Van Gaal; A Astrup
Journal:  Int J Obes (Lond)       Date:  2013-08-14       Impact factor: 5.095
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.